Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population.
Terao C, Ohmura K, Kochi Y, Ikari K, Okada Y, Shimizu M, Nishina N, Suzuki A, Myouzen K, Kawaguchi T, Takahashi M, Takasugi K, Murasawa A, Mizuki S, Iwahashi M, Funahashi K, Natsumeda M, Furu M, Hashimoto M, Ito H, Fujii T, Ezawa K, Matsubara T, Takeuchi T, Kubo M, Yamada R, Taniguchi A, Yamanaka H, Momohara S, Yamamoto K, Mimori T, Matsuda F. Terao C, et al. Among authors: takeuchi t. Arthritis Res Ther. 2015 Apr 18;17(1):104. doi: 10.1186/s13075-015-0623-4. Arthritis Res Ther. 2015. PMID: 25927497 Free PMC article. Review.
[Mediastinal teratoma].
Yamamoto K, Takeuchi T. Yamamoto K, et al. Among authors: takeuchi t. Ryoikibetsu Shokogun Shirizu. 1994;(4):363-5. Ryoikibetsu Shokogun Shirizu. 1994. PMID: 8007183 Review. Japanese. No abstract available.
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2).
Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H. Tanaka Y, et al. Among authors: takeuchi t. Mod Rheumatol. 2008;18(2):146-52. doi: 10.1007/s10165-008-0026-3. Epub 2008 Feb 19. Mod Rheumatol. 2008. PMID: 18283523 Free PMC article.
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).
Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, Saito K, Sekiguchi N, Sato E, Kameda H, Iwata S, Mochizuki T, Amano K, Tanaka Y. Takeuchi T, et al. Mod Rheumatol. 2008;18(5):447-54. doi: 10.1007/s10165-008-0077-5. Epub 2008 May 21. Mod Rheumatol. 2008. PMID: 18493716
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. Hashimoto J, et al. Among authors: takeuchi t. Mod Rheumatol. 2009;19(3):273-82. doi: 10.1007/s10165-009-0170-4. Epub 2009 May 19. Mod Rheumatol. 2009. PMID: 19452245 Clinical Trial.
5,608 results